|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for AMH(NM_000479.3) Search again
Product ID:
HQP007394
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
MIF, MIS
Gene Description:
anti-Mullerian hormone
Target Gene Accession:
NM_000479.3(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Validated result:
|
|
| A | B |
|
Each All-in-One™ qPCR Primer is experimentally validated to yield a single dissociation curve peak and to generate a single amplification of the correct size for the targeted gene. A cDNA Pool, containing reverse transcript products of 8 different human tissue total RNA(Liver, Testis,Muscle,Thyroid,Brain,Spleen,Stomach,Small Intestine)),was used as the qPCR validation template. qPCR was performed using 0.2 µM primer with 2XAll-in-One™ qPCR Mix (Catalog#: QP001,QP002,QP004,QP005). Reactions were incubated for 10min. at 95°C, followed by 40 cycles of 95°C for 10 sec.; 60°C, 20 sec. and 72°C, 15sec. using Bio-Rad iQ5™ Instrument. At the end of the last cycle, temperature was increased from 72 to 95°C to produce a melting curve. Panel A: Validated Result for Amplification Curve; Panel B: Validated Result for Melting Curve. |
|
Summary
Anti-Mullerian hormone is a member of the transforming growth factor-beta gene family which mediates male sexual differentiation. Anti-Mullerian hormone causes the regression of Mullerian ducts which would otherwise differentiate into the uterus and fallopian tubes. Some mutations in the anti-Mullerian hormone result in persistent Mullerian duct syndrome. [provided by RefSeq].
Gene References into function
- Administration of MIS to male mice induced IEX-1S mRNA in the prostate in vivo, suggesting that MIS may function as an endogenous hormonal regulator of NF-kappaB signaling and growth in the prostate gland.
- poor response in IVF, indicative of a diminished ovarian reserve, is associated with reduced baseline serum AMH concentrations
- Review. The role of AMH in gonadal development and its mutation in the persistent Mullerian duct syndrome is discussed.
- results indicate that serum AMH levels are strongly correlated with ovarian follicular status during the early follicular phase
- Increase of anti-Mullerian hormone(AMH) serum level in polycystic ovary syndrome is consequence of androgen-induced excess in small antral follicle number, and each follicle produces normal amount of AMH.
- Induction of p130 and p107 play an important role in the inhibition of growth of C33A cells by MIS.
- serum anti-Mullerian hormone (AMH) concentrations are elevated in normogonadotropic anovulatory infertile women (WHO 2) women, especially in those patients exhibiting polycystic ovary syndrome
- Anti-Mullerian hormone expression pattern in the human ovary follicle.
- In XXY adolescents, AMH and INHB were undetectable
- Serum AMH concentrations decrease over time both in women presenting with WHO 2 anovulatory infertility and in normal women. Decrease in WHO 2 patients is less pronounced despite distinctly elevated concentrations. May suggest retarded ovarian ageing.
- Recombinant follitropin and chorionic gonadotropin stimulation of the testis dramatically suppresses the secretion of AMH in hypogonadism.
- AMH promoter sequence variations or the previously proposed SF3a2-AMH fusion co-transcripts cannot be responsible for aberrant AMH expression leading to Mullerian duct degradation.
- AMH is also a gonadal tumor suppressor which mediates its effects through a specific type II receptor and the bone morphogenetic protein (BMP)-specific Smad proteins.
- a relative deficiency of AMH in primordial and transitional follicles in ovaries may contribute to disordered early follicle development in polycystic ovary syndrome
- Aggressive granulosa cell tumors(GCTs) retain high GATA-4 expression, whereas larger tumors lose proliferation-suppressing anti-Mullerian hormone expression. High GATA-4 expression in GCTs may serve as marker of poor prognosis.
- Increased MIS production in adolescent girls may represent an early manifestation of polycystic ovary syndrome
- AMH could thus be used as a diagnostic criterion and incorporated as such in the Rotterdam definition of polycystic ovary syndrome.
- MIS could potentially serve as a useful marker for identifying patients at risk for OHSS.
- Mullerian inhibiting substance regulates androgen-induced gene expression and growth in prostate cancer cells through a nuclear factor-kappaB-dependent Smad-independent mechanism.
- Its main physiological role is the induction of regression of Mullerian ducts in male fetuses but it also plays a role in Leydig cell steroidogenesis and in follicular development
- Hence, AMH exhibits a relatively stable expression during the menstrual cycle, making it an attractive determinant of ovarian activity.
- MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone
- serum anti-mullerian hormone (AMH) levels in Polysystic Ovary Syndrome patients were significantly higher than in healthy women
- Polymorphisms in the AMH and AMHR2 genes are associated with follicular phase E(2) levels, suggesting a role for AMH in the regulation of FSH sensitivity in the human ovary.
- Mullerian inhibiting substance has a role in response to ovarian stimulation
- Serum AMH and inhibin B are significantly lower in the men with nonobstructive azoospermia compared to the controls.
- anti-Mullerian hormone expression is stable during the menstrual cycle
- AMH concentrations are increased in peripubertal daughters of polycystic ovary syndrome women
- Oocytes are more likely to be fertilized when follicles are able to make high concentrations of AMH in the follicular fluid. AMH could be a prediction marker for fertilization.
- MIS is the earliest marker to change with agem has it has least intercycle variabilityane has the least intracycle variability; and 4) it may be informative if randomly obtained during the menstrual cycle. {REVIEW]
- Levels of AMH show a statistically significant change during the menstrual cycle and may influence the circulating gonadotropin and steroid hormone levels.
- Infertile patients with endometriosis have a decreased serum anti-Mullerian hormone.
- Granulosa cell production of AMH is augmented by pharmacologically induced increase in the intrafollicular androgen levels.
- Serum anti-Mullerian hormone (AMH) levels differentiate control from subfertile men but not men with different causes of subfertility
- Anti-Mullerian hormone levels in premature ovarian failure patients could identify women with persistent follicles.
- Suggest that there is no significant difference in follicular microenvironment in terms of AMH secretion between GnRH agonist/antagonist protocols and that follicular fluid AMH is a marker that reflects ovarian reserve and response to ovarian stimulation
- Fluctuations observed are smaller than intercycle variability and thus are not clinically relevant as far as AMH measurements for clinical purposes are concerned.
- The AMH and inhibin B levels on the day of oocyte retrieval are correlated to assisted reproductive outcome.
- preliminary data suggest that AMH levels indicate early ovarian decline among women with longer FMR1 repeat alleles; moreover, AMH appears to be a better marker than FSH in identifying this early decline.
- Review/Meta-Analysis: The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count.
- The insignificant variation of the AMH concentration with age, even in prepubertal girls, suggests that AMH expression is unrelated to menstrual cycle FSH cyclicity.
- AMH, an endocrine marker that reflects the transition of resting primordial follicles to growing follicles, declined to a time point 5 yr prior to the final mentrual period.
- AMHR genes are overexpressed by granulosa cells from stimulated follicles of women with polycystic ovary syndrome undergoing controlled ovarian hyperstimulation.
- The transition from resting to growing follicles leading to the development of secondary follicles showed the normal expression patterns of GDF-9 and AMH.